$NTGN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Neon Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Neon Therapeutics, Inc.. Get notifications about new insider transactions in Neon Therapeutics, Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 06 2020 | NTGN | Neon Therapeutics, ... | Zausner Meryl | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Zausner Meryl | Director | Option Exercise | D | 9.65 | 40,000 | 386,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Zausner Meryl | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | TEPPER ROBERT I | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | TEPPER ROBERT I | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | TEPPER ROBERT I | Director | Sell | D | 0.00 | 9,741,636 | 0 | 0 | 9.7 M to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | SHERWIN STEPHEN A | Director | Option Exercise | D | 2.65 | 5,000 | 13,250 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | SHERWIN STEPHEN A | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | SHERWIN STEPHEN A | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | SHERWIN STEPHEN A | Director | Sell | D | 0.00 | 45,000 | 0 | 0 | 45 K to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Pfeffer Cary | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Pfeffer Cary | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | LANDER ERIC S | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | LANDER ERIC S | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | LANDER ERIC S | Director | Sell | D | 0.00 | 134,000 | 0 | 0 | 134 K to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Kamen Robert | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Kamen Robert | Director | Option Exercise | D | 16.00 | 14,000 | 224,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | D | 7.56 | 28,000 | 211,680 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 2.65 | 155,373 | 411,738 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 6.13 | 105,000 | 643,650 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 10.20 | 58,005 | 591,651 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | D | 0.00 | 210,410 | 0 | 0 | 210.4 K to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Option Exercise | D | 12.00 | 100,000 | 1,200,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Option Exercise | D | 6.13 | 60,000 | 367,800 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Sell | D | 0.00 | 161,821 | 0 | 0 | 161.8 K to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Option Exercise | D | 6.13 | 100,000 | 613,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Option Exercise | D | 10.20 | 61,031 | 622,516 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Option Exercise | D | 5.80 | 192,759 | 1,118,002 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Sell | D | 0.00 | 196,965 | 0 | 0 | 197 K to 0 (-100.00 %) |
| May 06 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Option Exercise | D | 2.65 | 354,632 | 939,775 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Option Exercise | D | 6.13 | 200,000 | 1,226,000 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Option Exercise | D | 10.20 | 208,062 | 2,122,232 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Sell | D | 0.00 | 776,085 | 0 | 0 | 776.1 K to 0 (-100.00 %) |
| Mar 25 2020 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Sell | S | 2.17 | 50,358 | 109,483 | 940,590 | 990.9 K to 940.6 K (-5.08 %) |
| Mar 25 2020 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Sell | S | 2.19 | 84,286 | 184,780 | 856,304 | 940.6 K to 856.3 K (-8.96 %) |
| Mar 25 2020 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Sell | S | 2.20 | 117,400 | 258,538 | 1,896,176 | 2 M to 1.9 M (-5.83 %) |
| Mar 23 2020 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Sell | S | 2.51 | 9,050 | 22,760 | 990,948 | 1000 K to 990.9 K (-0.91 %) |
| Mar 23 2020 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Sell | S | 2.22 | 84,339 | 186,904 | 2,013,576 | 2.1 M to 2 M (-4.02 %) |
| Mar 02 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Payment of Exercise | F | 1.50 | 2,845 | 4,268 | 161,821 | 164.7 K to 161.8 K (-1.73 %) |
| Mar 02 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Payment of Exercise | F | 1.50 | 5,625 | 8,438 | 210,410 | 216 K to 210.4 K (-2.60 %) |
| Mar 02 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Payment of Exercise | F | 1.50 | 4,891 | 7,337 | 196,965 | 201.9 K to 197 K (-2.42 %) |
| Mar 02 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Payment of Exercise | F | 1.50 | 9,783 | 14,675 | 776,085 | 785.9 K to 776.1 K (-1.24 %) |
| Feb 27 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Payment of Exercise | F | 1.51 | 5,385 | 8,131 | 201,856 | 207.2 K to 201.9 K (-2.60 %) |
| Feb 27 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Payment of Exercise | F | 1.51 | 5,334 | 8,054 | 164,666 | 170 K to 164.7 K (-3.14 %) |
| Feb 27 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Payment of Exercise | F | 1.51 | 5,465 | 8,252 | 216,035 | 221.5 K to 216 K (-2.47 %) |
| Jan 13 2020 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Grant | A | 0.00 | 65,000 | 0 | 170,000 | 105 K to 170 K (+61.90 %) |
| Jan 13 2020 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Grant | A | 0.00 | 240,000 | 0 | 785,868 | 545.9 K to 785.9 K (+43.97 %) |
| Jan 13 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 65,000 | 0 | 221,500 | 156.5 K to 221.5 K (+41.53 %) |
| Jan 13 2020 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Grant | A | 0.00 | 65,000 | 0 | 207,241 | 142.2 K to 207.2 K (+45.70 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.24 | 22,322 | 27,644 | 156,500 | 178.8 K to 156.5 K (-12.48 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.31 | 23,000 | 30,231 | 178,822 | 201.8 K to 178.8 K (-11.40 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.37 | 20,000 | 27,498 | 201,822 | 221.8 K to 201.8 K (-9.02 %) |
| Nov 25 2019 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Grant | A | 0.00 | 75,000 | 0 | 105,000 | 30 K to 105 K (+250.00 %) |
| Nov 25 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 75,000 | 0 | 221,822 | 146.8 K to 221.8 K (+51.08 %) |
| Nov 25 2019 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Grant | A | 0.00 | 75,000 | 0 | 142,241 | 67.2 K to 142.2 K (+111.54 %) |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | Zausner Meryl | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | TEPPER ROBERT I | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | SHERWIN STEPHEN A | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | Pfeffer Cary | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | LANDER ERIC S | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | Kamen Robert | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Option Exercise | A | 6.13 | 60,000 | 367,800 | 60,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | Siegel Jolie | VP, General Counsel | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | A | 6.13 | 105,000 | 643,650 | 105,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 57,500 | 0 | 146,822 | 89.3 K to 146.8 K (+64.37 %) |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Option Exercise | A | 6.13 | 200,000 | 1,226,000 | 200,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Grant | A | 0.00 | 100,000 | 0 | 545,868 | 445.9 K to 545.9 K (+22.43 %) |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | ANG ROBERT | Chief Business Offi ... | Option Exercise | A | 6.13 | 40,000 | 245,200 | 40,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | ANG ROBERT | Chief Business Offi ... | Grant | A | 0.00 | 20,000 | 0 | 279,525 | 259.5 K to 279.5 K (+7.71 %) |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Option Exercise | A | 6.13 | 100,000 | 613,000 | 100,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Grant | A | 0.00 | 50,000 | 0 | 67,241 | 17.2 K to 67.2 K (+290.01 %) |
| Nov 07 2018 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 7.56 | 28,000 | 211,680 | 28,000 | |
| Nov 07 2018 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 7.56 | 28,000 | 211,680 | 28,000 | |
| Aug 22 2018 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Option Exercise | M | 2.65 | 18,868 | 50,000 | 314,607 | |
| Aug 22 2018 | NTGN | Neon Therapeutics, ... | O'Dowd Hugh | President & CEO | Buy | M | 2.65 | 18,868 | 50,000 | 445,868 | 427 K to 445.9 K (+4.42 %) |
| Jul 18 2018 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Option Exercise | M | 5.80 | 17,241 | 99,998 | 192,759 | |
| Jul 18 2018 | NTGN | Neon Therapeutics, ... | Al-Wakeel Yasir B. | Chief Financial Off ... | Buy | M | 5.80 | 17,241 | 99,998 | 17,241 | 0 to 17.2 K |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Third Rock Ventures III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,708,185 | 0 | 0 | |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Third Rock Ventures III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 45,000,000 | 0 | 0 | |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Third Rock Ventures III, L.P. | 10% Owner | Buy | C | 0.00 | 341,637 | 0 | 9,741,636 | 9.4 M to 9.7 M (+3.63 %) |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Third Rock Ventures III, L.P. | 10% Owner | Buy | C | 0.00 | 8,999,999 | 0 | 9,399,999 | 400 K to 9.4 M (+2,250.00 %) |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Option Exercise | C | 0.00 | 3,914,590 | 0 | 0 | |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Option Exercise | C | 0.00 | 5,000,000 | 0 | 0 | |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Option Exercise | C | 0.00 | 5,000,000 | 0 | 0 | |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Buy | P | 16.00 | 315,000 | 5,040,000 | 2,097,915 | 1.8 M to 2.1 M (+17.67 %) |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Buy | C | 0.00 | 782,917 | 0 | 1,782,915 | 1000 K to 1.8 M (+78.29 %) |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Buy | C | 0.00 | 999,998 | 0 | 999,998 | 0 to 1000 K |
| Jul 03 2018 | NTGN | Neon Therapeutics, ... | Access Industries Holdings LLC | 10% Owner | Buy | C | 0.00 | 999,998 | 0 | 999,998 | 0 to 1000 K |
| Jun 29 2018 | NTGN | Neon Therapeutics, ... | Hadley Harbor Master Investors ... | 10% Owner | Option Exercise | C | 0.00 | 3,329,610 | 0 | 0 | |
| Jun 29 2018 | NTGN | Neon Therapeutics, ... | Hadley Harbor Master Investors ... | 10% Owner | Buy | C | 0.00 | 665,922 | 0 | 665,922 | 0 to 665.9 K |
Page: 1